Stay updated on Duvelisib in Refractory Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.

Latest updates to the Duvelisib in Refractory Lymphoma Clinical Trial page
- Check7 days agoChange DetectedUpdates the site footer revision/version label from v3.5.0 to v3.5.3.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check44 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0 on the page. This update does not modify the study content or details.SummaryDifference0.0%

- Check58 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check79 days agoChange DetectedRevision: v3.4.2 is now displayed, replacing the previous v3.4.1. No study data or key page content appear to be affected.SummaryDifference0.0%

- Check87 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 and no user-facing content or study details were changed; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check101 days agoChange DetectedShow glossary and Hide glossary options were added to control glossary visibility. Capitalization adjustments were made for 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', and a new 'Revision: v3.4.0' stamp was introduced.SummaryDifference0.2%

Stay in the know with updates to Duvelisib in Refractory Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.